A respected RNAi therapeutics company.

Alnylam, Mount Sinai researchers discover svRNAs that play a crucial function in influenza A virus replication Alnylam Pharmaceuticals, Inc. , a respected RNAi therapeutics company, announced today the publication of new research findings in the journal Proceedings of the National Academy of Sciences by Alnylam researchers and collaborators from Mount Sinai College of Medicine facts about drugs . In the new study, Alnylam and Mount Sinai scientists discovered a novel class of virus-produced little non-coding RNAs, called small viral RNAs , which play a crucial function in the replication of influenza A virus.

Researchers are rallying to his protection, and 287 of them have got signed a petition protesting his sentencing and saying it is indicative of the development of government repression in Brazil. The government is apparently heading overboard in its tries to avoid biopiracy and, some say, making a good example out of van Roosmalen. This is all well and great. But this content is essentially a rehash of one that appeared in Character three weeks hence. As anyone who functions for scientific journals understands, this is par for the course. Articles that appear in Nature and Science turn out slightly modified in papers like the Occasions routinely. And I suppose that’s reasonable enough. But my complaint here is that nowhere in the article is the acknowledgement that Nature first reported the tale.